Network Version
UPF 1069 Data Sheet
| Product Name: | UPF 1069 |
 |
|---|---|---|
| CAS No.: | 1048371-03-4 | |
| Cat. No.: | HY-14478 | |
| MWt: | 279.29 | |
| Formula: | C17H13NO3 | |
| Purity : | >98% | |
| Solubility: | 10 mM in DMSO | |
| Mechanisms: | Target: Cancer | |
| Biological Activity: | ||
| UPF 1069 is a PARP inhibitor, with IC50s of 8 and 0.3 μM for PARP-1 and PARP-2, respectively. IC50 & Target: IC50: 8 μM (PARP-1), 0.3 μM (PARP-2)[1][2] In Vitro: UPF 1069 (Compound 55) is a PARP inhibitor, with IC50s of 8 and 0.3 μM for PARP-1 and PARP-2, respectively[1]. UPF 1069 (1 µM) reduces the residual PARP activity by approximately 80% of PARP-1-deficient fibroblasts, but only slightly inhibits the enzymic activity in wild-type fibroblasts. UPF 1069 (0.1-1 µM) markedly enhances CA1 hippocampal damage. UPF 1069 (10 µM) also exacerbates oxygen-glucose deprivation (OGD) damage in organotypic hippocampal slices. However, UPF 1069 alleviates the damage cuased by OGD in mixed cortical cell cultures, shows a potent neuroprotective activity both at a concentration (1 µM) selectively acting on PARP-2 and at a concentration (10 µM) inhibiting both PARP-1 and PARP-2 activities[2]. | ||
1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA
Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] Web:www.medchemexpress.com